TARA

Protara Therapeutics, Inc. is a biotechnology company focused on developing transformative therapies for serious medical conditions. Its lead investigational product, TARA-002, is a cell therapy aimed at treating non-muscle invasive bladder cancer and lymphatic malformations, with regulatory designations from the U.S. Food and Drug Administration. Additionally, the company is developing IV Choline Chloride, a phospholipid substrate replacement therapy for patients on parenteral support, addressing choline deficiency and associated liver damage. Protara operates primarily in the United States and targets oncology and nutritional support markets.